Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2951742 Biomarker Study in Migraine
NCT02766517Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galcanezumab in migraine, sponsored by Eli Lilly and Company. Primary endpoints: Capsaicin-Induced Dermal Blood Flow and Plasma Calcitonin Gene-Related Peptide Levels. Started Sep 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02766517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766517.